Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Status:
Completed
Trial end date:
2017-04-10
Target enrollment:
Participant gender:
Summary
To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasireotide LAR in
Japanese patients with active acromegaly or pituitary gigantism. Primary objective was to
assess the total-group efficacy of pasireotide LAR on the reduction of mean GH levels to <
2.5 µg/L and the normalization of insulin-like growth factor-1 (IGF-1) at 3 months of study
treatment.